[Hypoglycemia and cardiovascular risk]

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Disease in Diabetes

Background:

• Intensive glycemic control with glycated hemoglobin (HbA1c) targets below 7.0% has not demonstrated improved cardiovascular mortality in diabetic patients.
• Severe and recurrent hypoglycemia episodes are increasingly recognized as a potential contributor to the lack of cardiovascular benefit observed in intensive glucose-lowering therapy trials.

Purpose of the Study:

• To discuss the cardiovascular effects of hypoglycemia in the context of diabetes management.
• To review clinical trials investigating intensive glucose-lowering strategies and their impact on microvascular and macrovascular complications.
• To clarify the cardiovascular implications of current non-insulin antidiabetic drugs that do not induce hypoglycemia.

Main Methods:

• Review of existing literature on intensive glycemic control in diabetes.
• Analysis of cardiovascular outcomes from major clinical trials focusing on glucose-lowering strategies.
• Evaluation of the safety and cardiovascular profiles of non-hypoglycemia-inducing diabetes medications.

Main Results:

• Intensive glycemic control strategies have not shown a reduction in cardiovascular mortality.
• Hypoglycemia, particularly severe episodes, is a significant concern associated with intensive glucose-lowering therapies.
• Certain non-insulin medications for diabetes exhibit neutral or potentially beneficial cardiovascular effects without increasing hypoglycemia risk.

Conclusions:

• The failure to observe cardiovascular benefits with intensive glycemic control may be linked to the adverse effects of hypoglycemia.
• Future diabetes treatment strategies should consider the cardiovascular risks associated with hypoglycemia and prioritize safer glucose-lowering agents.
• Non-insulin drugs that avoid hypoglycemia represent a promising therapeutic option for managing diabetes and its cardiovascular complications.